Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults
Open Access
- 14 July 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 282 (2) , 137-144
- https://doi.org/10.1001/jama.282.2.137
Abstract
Influenza type A and B viruses cause illness in 10% to 20% of the population each year.1 Prominent manifestations of illness include decreased ability to perform daily activities and increased health care resource use. Among working adults, influenza accounts for millions of work-loss days and physician office visits each year.2,3 Although healthy, working adults are not currently targeted for routine annual vaccination,4 immunization with inactivated influenza virus vaccines can be associated with substantial health and economic benefits for this group.5Keywords
This publication has 11 references indexed in Scilit:
- The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in ChildrenNew England Journal of Medicine, 1998
- Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patientsPublished by American Medical Association (AMA) ,1997
- Sickness Absence Following a Campaign of Vaccination against Influenza in the WorkplaceOccupational Medicine, 1996
- The Effectiveness of Vaccination against Influenza in Healthy, Working AdultsNew England Journal of Medicine, 1995
- A Randomized Controlled Trial of Cold-Adapted and Inactivated Vaccines for the Prevention of Influenza A DiseaseThe Journal of Infectious Diseases, 1994
- Estimates of the US health impact of influenza.American Journal of Public Health, 1993
- Advances in Influenza Virus Vaccine ResearchaAnnals of the New York Academy of Sciences, 1993
- Comparison of Heterotypic Protection against Influenza A/Taiwan/86 (H1N1) by Attenuated and Inactivated Vaccines to A/Chile/83-like VirusesThe Journal of Infectious Diseases, 1991
- ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTIONThe Lancet, 1984
- Vaccination against influenza: a five-year study in the Post OfficeEpidemiology and Infection, 1979